Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Head & Neck 2Gynecologic 2Gastrointestinal 2Breast 2Dermatologic 1

Conditions

Melanoma 3Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 12Nivolumab 10cemiplimab 5avelumab 5Ipilimumab 5atezolizumab 4poly ICLC 3fludarabine 3durvalumab 3Gemcitabine 3Cyclophosphamide 3Biopsy 3utomilumab 2ulixertinib 2pertuzumab 2osimertinib 2aldesleukin 2Trastuzumab 2Standard of Care 2Sirolimus 2Radiosurgery 2Psychiatric Rehabilitation 2Magnetic Resonance Spectroscopy 2Interleukin-2 2Immunoglobulin G 2Docetaxel 2Disulfides 2Blood Specimen Collection 2zimberelimab 1vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × zimberelimab × Dermatologic × Clear all
NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

Phase 1 Completed
48 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡